Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Chiasma Stories

2012-06-26 10:24:10

Chiasma Developing Oral Alternative to Injectable Somatostatin Analogs; Phase 3 Trial Under Way HOUSTON, June 26, 2012 /PRNewswire-USNewswire/ -- Chiasma, a privately held biopharma company, today presented data at the annual meeting of The Endocrine Society (ENDO 2012) that show Octreolin, an investigational new oral drug being developed for use in acromegaly, reduced pituitary growth hormone secretion in healthy volunteers as effectively as shown in published studies of injectable...

2011-09-14 07:53:00

NEW YORK and JERUSALEM, Sept. 14, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Monday, September 19, 2011 at 1:30 PM. Chiasma's investigational new drug Octreolin(TM) is an oral form of octreotide acetate being developed first for the oral treatment of acromegaly, a hormonal...

2010-06-27 23:01:00

NEW YORK and JERUSALEM, June 28 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration (FDA) has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer (TPE) technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone. If a New Drug Application...

2009-01-12 01:24:00

JERUSALEM, Jan. 12 /PRNewswire/ -- Chiasma, Inc. today made the following announcements: Using the Company's proprietary Transient Permeability Enhancer (TPE) technology, scientists at Chiasma have delivered drugs orally in animal models that previously had only been available via injection. The TPE platform has successfully transported proteins, peptides, polysaccharides and non-soluble small molecules into the blood to achieve clinically meaningful bioavailability levels. The TPE...